ObjectiveTo observe the clinical efficacy of trastuzumab combined with cisplatin in the treatment of patients with human epidermal growth factor receptor 2（HER2） positive breast carcinoma. MethodsA total of 65 patients with HER2 positive breast carcinoma who received modified radical mastectomy in our hospital from January 2016 to January 2018 were selected as the research objects, and they were divided into two groups according to the postoperative chemotherapy regimen. The control group (30 cases) was given cisplatin chemotherapy after operation, and the experimental group (35 cases) was treated with trastuzumab combined with cisplatin chemotherapy after operation. The clinical efficacy and long-term survival rate were compared between the two groups. ResultsAfter 4 to 6 cycles of chemotherapy, the total effective rate of treatment of the experimental group (82.86%) was significantly higher than that of the control group (56.67%), with a statistically significant difference (P＜0.05). After the treatment courses, the scores of all dimensions of the mos 36-item short form health survey (SF-36) in the experimental group were significantly higher than those in the control group, with statistically significant differences (P＜0.05). After the treatment courses, 3-year follow-up analysis of the patients showed that the mortality of the experimental group (31.4%) was significantly lower than that of the control group (63.3%), and the progression-free survival rate (60.0%) was significantly higher than that of the control group (26.7%), with statistically significant differences (P＜0.05). ConclusionTrastuzumab combined with cisplatin chemotherapy can significantly improve the clinical efficacy, quality of life and postoperative survival rate of patients with HER2 positive breast carcinoma, which has important reference value for clinical treatment.

无